PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS

Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: K. Simpson, N. Marlow, J. Shaw, А. V. Rudakova
格式: Artigo
語言:Inglês
出版: Paediatrician Publishers, LLC 2012-08-01
叢編:Pediatričeskaâ Farmakologiâ
主題:
juvenile idiopathic arthritis
adalimumab
cost-effectiveness analysis
在線閱讀:https://www.pedpharma.ru/jour/article/view/302
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍